The fluorine-18-labeled positron emission tomography (PET) radiotracer [(18) F]MK-9470 is a selective, high affinity inverse agonist that has been used to image the cannabinoid receptor type 1 in human brain in healthy and disease states. This report describes a simplified, one-step [(18) F]radiofluorination approach using a GE TRACERlab FXFN module for the routine production of this tracer. The one-step synthesis, by [(18) F]fluoride displacement of a primary tosylate precursor, gives a six-fold increase in yield over the previous two-step method employing O-alkylation of a phenol precursor with 1,2-[(18) F]fluorobromoethane. The average radiochemical yield of [(18) F]MK-9470 using the one-step method was 30.3 ± 11.7% (n = 12), with specific activity in excess of 6 Ci/µmol and radiochemical purity of 97.2 ± 1.5% (n = 12), in less than 60 min. This simplified, high yielding, automated process was validated for routine GMP production of [(18) F]MK-9470 for clinical studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jlcr.3219 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rimota-Gd: Paramagnetic Probe for In Vivo MRI Studies of the Cannabinoid 1 Receptor Distribution in the Mouse Brain.
ACS Chem Neurosci
December 2024
iHuman Institute, ShanghaiTech University, Shanghai 200031, China.
The cannabinoid 1 receptor (CB1) is highly expressed in the central nervous system, where its physiological functions include the regulation of energy balance, pain, and addiction. Herein, we develop and validate a technique to use magnetic resonance imaging (MRI) to investigate the distribution of CB1 across mouse brains with high spatial resolution, expanding previously described in vitro studies and in vivo studies with positron emission tomography (PET). To support the MRI investigations, we developed a ligand that is specific for in vivo neuroimaging of CB1.
View Article and Find Full Text PDFAge, gender and body-mass-index relationships with in vivo CB receptor availability in healthy humans measured with [C]OMAR PET.
Neuroimage
December 2022
Department of Psychiatry, Yale University School of Medicinev, New Haven, CT 06511, United States; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, United States; Department of Neurology, Yale University School of Medicine, United States.
Brain cannabinoid 1 receptors (CB1Rs) contribute importantly to the regulation of autonomic tone, appetite, mood and cognition. Inconsistent results have been reported from positron emission tomography (PET) studies using different radioligands to examine relationships between age, gender and body mass index (BMI) and CB1R availability in healthy individuals. In this study, we examined these variables in 58 healthy individuals (age range: 18-55 years; 44 male; BMI=27.
View Article and Find Full Text PDFCannabinoid receptor availability modulates the magnitude of dopamine release in vivo in the human reward system: A preliminary multitracer positron emission tomography study.
Addict Biol
May 2022
Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
The established role of dopamine (DA) in the mediation of reward and positive reinforcement, reward processing is strongly influenced by the type 1 cannabinoid receptors (CB Rs). Although considerable preclinical evidence has demonstrated several functional CB R-DA interactions, the relation between human CB R availability, DA release capacity and drug-reinforcing effects has been never investigated so far. Here, we perform a multitracer [ F]MK-9470 and [ F]fallypride positron emission tomography (PET) study in 10 healthy male subjects using a placebo-controlled and single-blinded amphetamine (AMPH) (30 mg) administration paradigm to (1) investigate possible functional interactions between CB R expression levels and DA release capacity in a normo-DAergic state, relating in vivo AMPH-induced DA release to CB R availability, and (2) to test the hypothesis that the influence of striatal DAergic signalling on the positive reinforcing effects of AMPH may be regulated by prefrontal CB R levels.
View Article and Find Full Text PDFQuantification of the Cannabinoid Type 1 Receptor Availability in the Mouse Brain.
Front Neuroanat
November 2020
Department of Nuclear Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
: The endocannabinoid system is involved in several diseases such as addictive disorders, schizophrenia, post-traumatic stress disorder, and eating disorders. As often mice are used as the preferred animal model in translational research, in particular when using genetically modified mice, this study aimed to provide a systematic analysis of cannabinoid type 1 (CB1) receptor ligand-binding capacity using positron emission tomography (PET) using the ligand [F]MK-9470. We then compared the PET results with literature data from immunohistochemistry (IHC) to review the consistency between protein expression and ligand binding.
View Article and Find Full Text PDFRegional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease.
Eur J Nucl Med Mol Imaging
October 2019
Nuclear Medicine and Molecular Imaging, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Purpose: The endocannabinoid system plays a regulatory role in a number of physiological functions, including motor control but also mood, emotion, and cognition. A number of preclinical studies in Parkinson's disease (PD) models demonstrated that modulating the type 1 cannabinoid receptor (CBR) may improve motor symptoms and components of cognitive processing. However, the relation between CBR, cognitive decline and behavioral symptoms has not been investigated in PD patients so far.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!